BURLINGTON, Mass. (February 23, 2011) – InfraReDx, Inc., a medical device company providing intelligent cardiovascular diagnostic imaging technologies, today announced that its LipiScan™ IVUS Coronary Imaging System will be featured in several presentations during the annual Cardiovascular Research Technologies (CRT) 2011 meeting, being held February 27 through March 1, 2011 at the Omni Shoreham Hotel in Washington, D.C. The oral presentations and panel will discuss the clinical applications of the company’s coronary imaging technology in identifying and characterizing lipid core plaque during cardiac catheterization procedures to improve stenting safety and patient care. The LipiScan IVUS Coronary Imaging System is the world’s first and only intravascular imaging system that combines and co-registers grayscale intravascular ultrasound (IVUS) with the company’s proprietary near infrared spectroscopy lipid core plaque detection technology.
“We are very pleased that LipiScan IVUS will be discussed in many presentations at CRT,” said James E. Muller, M.D., founder, chairman and chief medical officer of InfraReDx. “The response to our launch of this novel product has been excellent, and we are already receiving reports of many important cases in which the combined NIR and IVUS information helped clarify the extent of coronary atherosclerosis.”
On Monday, February 28, the company’s LipiScan IVUS Coronary Imaging System will be highlighted as part of the “Vulnerable Plaque Summit & Atherosclerosis Lipid Management” Science Track during the following presentations:
• Dr. Muller will give a presentation titled “Near Infrared Spectroscopy (NIRS): Technology Update” at 12:50 p.m.
• Brijeshwar S. Maini, M.D., F.A.C.C., a cardiology specialist at the Moffitt Heart and Vascular Group in Pennsylvania, will give a presentation titled “Near Infrared Spectroscopy: Case Studies and Clinical Relevance” at 1 p.m.
• Patrick W. Serruys, M.D., Ph.D., professor of interventional cardiology, Erasmus University, Thoraxcentrum Rotterdam, Netherlands will give a presentation titled “IVUS-VH vs. LipiScan: Are We Interrogating the Same Anatomic Substrate?” at 1:10 p.m.
On Tuesday, March 1, InfraReDx technology will be featured as part of the “Cardiovascular Innovations” Technology Track during the following presentations:
• James A. Goldstein, M.D., director of cardiac research and education for the William Beaumont Hospital in Michigan, will present a summary of the LipiScan IVUS Coronary Imaging System and conduct a question and answer session at 7:16 a.m.
• Dr. Muller will give a presentation titled “Lipid Detection: InfraReDx Technology Integrated with IVUS” at 8:50 a.m.
• Dr. Muller will participate on a panel titled “How Will New Invasive Imaging Assist in Complex Interventions?
What Will be Changed in the Cath Lab of the Future?” at 9:50 a.m.
Additionally, the company will be exhibiting at booth #114 during the conference.
About the LipiScan™ IVUS Coronary Imaging System
The LipiScan IVUS Coronary Imaging System employs proprietary optical imaging technology to overcome the challenges of heart motion, blood interference, and vascular access to perform NIR spectroscopic analysis of the vessel and produce a chemical map of lipid-core plaque called a Chemogram™. The system also provides physicians with a traditional IVUS image that shows plaque location, degree of stenosis and degree of stent expansion. At the same time, optical data are recorded that permit identification and co-localization of lipid core plaques. This innovative multi-modality analysis is accomplished directly in the catheterization laboratory during the coronary intervention via a single catheter pullback procedure. The data are immediately available to the physician to help guide the stenting procedure.
About InfraReDx, Inc.
InfraReDx, Inc. is a privately funded medical device company improving patient care through the development and commercialization of intelligent imaging technologies to improve the diagnosis and treatment of coronary artery disease. InfraReDx’s LipiScan™ IVUS Coronary Imaging System is the first and only available catheter to combine both near-infrared spectroscopy (NIR) and intravascular ultrasound (IVUS) technologies to both visualize and characterize the intracoronary lipid core plaques (LCP) suspected of causing the majority of heart attacks. Founded in 1998, InfraReDx is headquartered in Burlington, Massachusetts. For more information, visit www.infraredx.com.
Susan Heins (media)
Pure Communications, Inc.
Vice President of Marketing
Source: InfraReDx, Inc.